Literature DB >> 8510220

Human immunodeficiency virus type 1 Vpu has a CD4- and an envelope glycoprotein-independent function.

R J Geraghty1, A T Panganiban.   

Abstract

Vpu is a 16-kDa membrane-associated phosphoprotein that is expressed from the same, singly spliced message as the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein precursor, gp160. Previous studies suggest that Vpu functions in the late stages of viral replication, possibly in virus egression from the cell. Recently, it has been demonstrated that Vpu functions to allow gp160 to be more efficiently processed by disrupting CD4-gp160 complexes generated by transfection of HeLa cells. We show here that the lack of expression of intact Vpu results in a 90% reduction in infectious virus produced over a single round of replication from HeLa cells in the absence of CD4 expression. This reduction persists when HIV-1 particles are pseudotyped with the HIV-2 or amphotropic murine leukemia virus envelope glycoprotein. Pulse-chase analysis of HIV-1 capsid protein (p24) in the absence of CD4 and envelope glycoprotein demonstrates that the rate of virus release is reduced when Vpu is not expressed. Our findings indicate that Vpu has a function involving particle release not dependent on CD4 or envelope glycoprotein expression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8510220      PMCID: PMC237788          DOI: 10.1128/JVI.67.7.4190-4194.1993

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

Authors:  T Klimkait; K Strebel; M D Hoggan; M A Martin; J M Orenstein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes.

Authors:  R L Willey; F Maldarelli; M A Martin; K Strebel
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.

Authors:  E O Freed; E L Delwart; G L Buchschacher; A T Panganiban
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

4.  Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.

Authors:  J Sodroski; W C Goh; C Rosen; K Campbell; W A Haseltine
Journal:  Nature       Date:  1986 Jul 31-Aug 6       Impact factor: 49.962

5.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein.

Authors:  K Strebel; T Klimkait; F Maldarelli; M A Martin
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160.

Authors:  E O Freed; D J Myers; R Risser
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.

Authors:  K A Page; N R Landau; D R Littman
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

9.  Functional role of human immunodeficiency virus type 1 vpu.

Authors:  E F Terwilliger; E A Cohen; Y C Lu; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

10.  Identification of a protein encoded by the vpu gene of HIV-1.

Authors:  E A Cohen; E F Terwilliger; J G Sodroski; W A Haseltine
Journal:  Nature       Date:  1988-08-11       Impact factor: 49.962

View more
  16 in total

1.  Functional interaction of human immunodeficiency virus type 1 Vpu and Gag with a novel member of the tetratricopeptide repeat protein family.

Authors:  M A Callahan; M A Handley; Y H Lee; K J Talbot; J W Harper; A T Panganiban
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

2.  Distinct functions and requirements for the Cys-His boxes of the human immunodeficiency virus type 1 nucleocapsid protein during RNA encapsidation and replication.

Authors:  M D Schwartz; D Fiore; A T Panganiban
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Persistent infection of macaques with simian-human immunodeficiency viruses.

Authors:  J T Li; M Halloran; C I Lord; A Watson; J Ranchalis; M Fung; N L Letvin; J G Sodroski
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule.

Authors:  E Tiganos; X J Yao; J Friborg; N Daniel; E A Cohen
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Compatibility of Vpu-like activity in the four groups of primate immunodeficiency viruses.

Authors:  S Iida; T Fukumori; Y Oshima; H Akari; A H Koyama; A Adachi
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

Review 6.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

7.  Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.

Authors:  G D Ritter; G Yamshchikov; S J Cohen; M J Mulligan
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus.

Authors:  N L Michael; G Chang; L A d'Arcy; P K Ehrenberg; R Mariani; M P Busch; D L Birx; D H Schwartz
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?

Authors:  S Bour; U Schubert; K Peden; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.

Authors:  Amy J Andrew; Eri Miyagi; Sandra Kao; Klaus Strebel
Journal:  Retrovirology       Date:  2009-09-08       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.